Epidemiologic study in a real‐world analysis of patients with treatment for psoriasis in the French national health insurance database

Abstract

Background Psoriasis is one of the most frequent chronic inflammatory dermatoses in the world. Data on the prevalence of psoriasis in adults differ depending on the study. Objective To estimate the prevalence of patients with treatment for psoriasis in France and to identify and characterize patients receiving systemic treatments. Methods This was a French, nationwide cohort study based on health administrative data from the French national health insurance scheme linked to the national hospital discharge database (SNDS‐PMSI). All adults with psoriasis registered in the SNDS between 1 January 2008 and 31 December 2016 were eligible for inclusion. All patients with a new prescription for a systemic treatment for psoriasis were included. Results A total of 874 549 patients were identified as having psoriasis (mean ± SD age 53.8 ± 17 years; 52.4% males); 112 969 (13%) had filled at least one prescription for a systemic medication used to treat psoriasis. The prevalence of patients with treatment for psoriasis was estimated at 1.3%. Overall, 73 168 and 16 545 were new users of conventional systemic treatments and biologics, respectively. The most frequent comorbidities associated with psoriasis were hypertension, dyslipidaemia, diabetes and chronic obstructive pulmonary disease. Conclusion The prevalence of psoriasis we found was lower than in other studies. It was probably underestimated because we identified only patients with treatment for psoriasis. Our results concerning comorbidities associated with psoriasis patients requiring systemic treatment were similar to those from other published studies using other data sources, highlighting our ability to catch moderate‐to‐severe psoriasis. This study highlights the usefulness and reliability of the use of insurance databases in studies, because they allow for a better application to the general population.

Health insurance coverage and timely antenatal care attendance in sub-Saharan Africa

“…For example, countries such as China which has a population of over 1.3 billion people ensures health insurance coverage for its populace [ 7 ]. Several countries including the USA [ 8 ], Taiwan [ 9 ], and France [ 10 ] have all instituted national health insurance. In sub-Saharan Africa (SSA), countries like Ghana [ 3 ] and Nigeria [ 11 ] have health insurance schemes that aims to promote UHC and limit catastrophic health expenditure.…”

The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study

“…Psoriasis is a systemic inflammatory disease with a growing body of comorbidities interesting several tissues, from lungs to joints. 1,2 Moderate to severe psoriatic patients (PASI>10) that failed conventional systemic therapies may undergo biological tehrapies, such as IL-17 inhibitors. Ixekizumab is monoclonal antibody that inhibits IL-17A (IL-17A), indicated in the treatment of Ps and psoriatic arthritis (PsA).…”

“…Psoriasis (Ps) does not afflict preferentially skin and joints, but are only the sites more assessable. Psoriasis is a systemic inflammatory disease with a growing body of comorbidities interesting several tissues, from lungs to joints 1,2 …”

Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France

“…Firstly, our population received both topical and systemic treatments that are reimbursed in the context of psoriasis – thus minimizing selection bias. Secondly, our study population had much the same characteristics as previously described populations of patients with severe psoriasis 33 . Lastly, a recent systematic review validated the definition we used 25 .…”